Education
About Us
Working with TipRanks
Follow Us
Acumen Pharmaceuticals (ABOS)
NASDAQ:ABOS
ABOS Stock Chart & Stats
$2.48
-$0.08(-4.37%)
At close: 4:00 PM EST
$2.48
-$0.08(-4.37%)
Day’s Range― - ―
52-Week Range$0.86 - $3.05
Previous CloseN/A
Volume101.31K
Average Volume (3M)415.59K
Market Cap
$145.38M
Enterprise Value$134.23M
Total Cash (Recent Filing)$126.61M
Total Debt (Recent Filing)$30.84M
Price to Earnings (P/E)―
Beta2.31
Next Earnings
Mar 30, 2026EPS Estimate
-0.45Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.44
Shares Outstanding60,573,425
10 Day Avg. Volume506,634
30 Day Avg. Volume415,590
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)0.57
Price to Sales (P/S)0.00
P/FCF Ratio-1.20
Enterprise Value/Market Cap0.92
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-3.05K
Enterprise Value/Ebitda-1.04
Forecast
1Y Price Target
$7.00Price Target Upside182.26% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Funding And Partnership StructureCompany funding through the upcoming critical readout and a back‑end loaded collaboration structure align incentives and reduce near‑term capital pressure.
Mechanism Of ActionAntibody design that preferentially targets toxic oligomers rather than abundant plaque may lead to greater clinical effectiveness and a safer profile versus competing approaches.
Regulatory PathwayRegulatory acceptance of a subcutaneous induction filing could enable a more convenient dosing option, improving patient access and supporting broader adoption of anti‑amyloid therapies.
Bears Say
Efficacy Endpoint UncertaintyReliance on plaque removal as primary evidence in the subcutaneous filing creates uncertainty that measurable cognitive improvement will follow without confirmatory functional evidence.
Regulatory And Post‑approval ObligationsApproval based on surrogate plaque endpoints could prompt additional regulatory requirements or confirmatory trials, extending uncertainty around real‑world clinical benefit.
Safety Risk — Brain Swelling (ARIA)Subcutaneous formulation may not substantially reduce the brain swelling risk observed with intravenous dosing, limiting any improvement in the therapy's overall risk–benefit profile.
Acumen Pharmaceuticals News
ABOS FAQ
What was Acumen Pharmaceuticals’s price range in the past 12 months?
Acumen Pharmaceuticals lowest stock price was $0.85 and its highest was $3.05 in the past 12 months.
What is Acumen Pharmaceuticals’s market cap?
Acumen Pharmaceuticals’s market cap is $145.38M.
When is Acumen Pharmaceuticals’s upcoming earnings report date?
Acumen Pharmaceuticals’s upcoming earnings report date is Mar 30, 2026 which is in 47 days.
How were Acumen Pharmaceuticals’s earnings last quarter?
Acumen Pharmaceuticals released its earnings results on Nov 12, 2025. The company reported -$0.44 earnings per share for the quarter, beating the consensus estimate of -$0.603 by $0.163.
Is Acumen Pharmaceuticals overvalued?
According to Wall Street analysts Acumen Pharmaceuticals’s price is currently Undervalued.
Does Acumen Pharmaceuticals pay dividends?
Acumen Pharmaceuticals does not currently pay dividends.
What is Acumen Pharmaceuticals’s EPS estimate?
Acumen Pharmaceuticals’s EPS estimate is -0.45.
How many shares outstanding does Acumen Pharmaceuticals have?
Acumen Pharmaceuticals has 60,573,425 shares outstanding.
What happened to Acumen Pharmaceuticals’s price movement after its last earnings report?
Acumen Pharmaceuticals reported an EPS of -$0.44 in its last earnings report, beating expectations of -$0.603. Following the earnings report the stock price went down -1.015%.
Which hedge fund is a major shareholder of Acumen Pharmaceuticals?
Currently, no hedge funds are holding shares in ABOS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Acumen Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.00 (182.26% Upside)
$7.00 (182.26% Upside)
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.2%
Last 30 Days ▲ 109.1%
Last 30 Days ▲ 109.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-25.87%
12-Months-Change
Fundamentals
Return on Equity
-85.93%
Trailing 12-Months
Asset Growth
-40.50%
Trailing 12-Months
Company Description
Acumen Pharmaceuticals
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
ABOS Company Deck
ABOS Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in clinical trials, strategic partnerships, and financial management, with a focus on advancing Alzheimer's treatments. However, the operational loss was a noted concern.View all ABOS earnings summariesABOS Stock 12 Month Forecast
Average Price Target
$7.00
▲(182.26% Upside)
Technical Analysis
Ownership Overview
27.13% Insiders
7.79% Mutual Funds
38.60% Other Institutional Investors
23.92% Public Companies and Individual Investors